Abstract 1442P
Background
We previously reported that intratumoral HER2 heterogeneity was associated with limited treatment efficacy to trastuzumab-based chemotherapy for HER2 positive advanced gastric cancer (AGC). In this study, we investigated the mechanism of resistance associated with intratumoral HER2 heterogeneity through ctDNA analysis.
Methods
We enrolled tissue-confirmed HER2 positive AGC patients who received chemotherapy with anti-HER2 and anti-PD-1 dual-targeted therapy from a phase Ib clinical trial. We compared clinical characteristics, gene alterations that obtained by ctDNA panel (Guardant 360®), and clinical outcomes of chemotherapy with the dual targeted therapy according to the intratumor HER2 heterogeneity status.
Results
Somatic alterations in ctDNA were detected in 20 of 21 (95.2%) patients. Among them, HER2-homo was observed in 8 of 20 patients (40.0%). AGC patients with HER2-homo tended to have a higher proportion of immunohistochemistry 3+ than those with HER2-hetero (100% vs 58.3%, P = 0.055), and the ERBB2 copy number variant (CNV) detection rate in HER2-homo tended to be higher than those in HER2-hetero (87.5% vs 41.7%, P = 0.07). In addition, ctDNA ERBB2 copy number in HER2-homo was significantly higher than those in HER2-hetero (4.5 copies vs 2.51 copies, P = 0.045). In contrast, the proportion of single nucleotide variant (SNV)s or CNVs associated with the cell cycle tended to be lower in HER2 homo than in HER2 hetero (25% vs 75%, P = 0.065). Regarding clinical outcomes of chemotherapy with HER2 and PD-1 dual targeted therapy, both median progression free survival (PFS) and overall survival (OS) in the HER2-homo was tended to be longer than that in the HER2-hetero (PFS: 20.8 months [95% CI] 8.4–NA] vs. 11.3 months [95% CI 5.5–16.3]; hazard ratio (HR) 0.36; 95% CI 0.11–1.24; P = 0.1, OS: NA [95% CI 14–NA] vs. 21.0 months [95% CI 10–NA]; HR 0.36; 95% CI 0.06–1.98; P = 0.24).
Conclusions
Intra-tumor HER2 heterogeneity, classified to homogenous or heterogenous, may be a useful biomarker associated with distinct tumor biology to predict the clinical efficacy of anti-HER2 and anti- PD-1 dual targeted therapy in patients with HER2 positive AGC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ono Pharmaceutical Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1919P - Clinical actionability of germline alterations in pleural mesothelioma: Results from a multicentric study
Presenter: Luigi Cerbone
Session: Poster session 18
1918P - Real-world efficacy and toxicity of combination immunotherapy in mesothelioma: North East of England experience
Presenter: Manal Elgendy
Session: Poster session 18
1917P - Updated survival and vaccine response from the NIPU trial: A randomised, phase II study evaluating nivolumab and ipilimumab with or without UV1 vaccination in patients with pleural mesothelioma
Presenter: Vilde Haakensen
Session: Poster session 18
1916P - Methylation subtypes correlate with tumor immune contextures and outcome to ICI therapy of pleural mesothelioma (PM) patients: The NIBIT EPI-MESO study
Presenter: LUANA CALABRO
Session: Poster session 18
1915P - Phase I trial of adjuvant pembrolizumab after radiation therapy for lung-intact malignant pleural mesothelioma
Presenter: Matthew Ning
Session: Poster session 18
1914P - Nintedanib(N) as switch maintenance treatment in malignant pleural mesothelioma (MPM) (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Presenter: Omar Abdel-Rahman
Session: Poster session 18
1913P - Five year results of transbronchial microwave ablation of lung malignancies with electromagnetic navigation guidance
Presenter: Joyce Chan
Session: Poster session 18
1912P - AI-based early prediction of radiation pneumonitis in stage III NSCLC patients
Presenter: Samaantha Bove
Session: Poster session 18
1911P - Implementation of remote patient monitoring in thoracic oncology: A real-world experience from 489 pts across 41 centers in France
Presenter: Laurent Greillier
Session: Poster session 18